Chronic leukemias

Chronic Leukemias: High-Yield Clonal Pathologies & Diagnostics

Chronic leukemias are neoplastic proliferations of mature, differentiated myeloid or lymphoid cells within the bone marrow and peripheral blood. Unlike acute leukemias, which present with rapid accumulation of non-functional blasts, chronic leukemias progress insidiously over years. The circulating cells are fully mature in appearance, though functionally abnormal.

1. Chronic Myelogenous Leukemia (CML)

CML is a myeloproliferative neoplasm characterized by the unregulated overproduction of the entire granulocytic cell line (neutrophils, metamyelocytes, myelocytes, and basophils). It primarily affects adults aged 40 to 60.

• The Molecular Hallmark: Driven by a reciprocal translocation, t(9;22), known as the Philadelphia Chromosome. This fuses the BCR gene on chromosome 22 with the ABL1 gene on chromosome 9, creating a constitutively active tyrosine kinase that drives cell division.
• Clinical Findings: Massive splenomegaly (extramedullary hematopoiesis causing early satiety), profound leukocytosis (often exceeding 100,000 cells/uL), and absolute basophilia.
• Leukocyte Alkaline Phosphatase (LAP) Score: Characteristically low or zero in CML due to dysfunctional white cells. This distinguishes CML from a leukemoid reaction (a massive WBC spike driven by severe infection, where the LAP score is high).
• Phases of Progression: Progresses from a stable Chronic Phase to an Accelerated Phase, ultimately culminating in a Blast Crisis (acute leukemia transformation: 80% AML, 20% ALL) when marrow blasts reach or exceed 20%.
• Targeted Treatment: Successfully managed with Imatinib, a small-molecule tyrosine kinase inhibitor (TKI) that blocks the ATP-binding pocket of the BCR-ABL1 fusion protein.

2. Chronic Lymphocytic Leukemia (CLL)

CLL involves a neoplastic proliferation of morphologically mature, immunologically incompetent B-lymphocytes. It is the most common leukemia in Western countries, typically diagnosed in elderly patients (median age around 70).

• Immunophenotype and Genetics: CLL cells characteristically express the T-cell marker CD5 along with normal B-cell markers (CD19, CD20, and CD23). Deletion of 13q is the most common cytogenetic abnormality (favorable prognosis), while deletion of 17p alters p53 (poor prognosis).
• Clinical Presentations: Frequently discovered incidentally as asymptomatic isolated lymphocytosis on a routine CBC. Associated with generalized painless lymphadenopathy, hypogammaglobulinemia (precluding recurrent bacterial infections due to low IgG/IgA), and Autoimmune Hemolytic Anemia (AIHA).
• Peripheral Smear Finding: Fragile leukemic cells frequently rupture during slide preparation, creating characteristic smudge cells.
• Richter Transformation: Sudden, acute transformation of CLL into an aggressive, high-grade non-Hodgkin lymphoma (typically Diffuse Large B-Cell Lymphoma), presenting with rapidly enlarging lymph nodes and systemic B-symptoms.

3. High-Yield Summary Table